Table 1.

Characteristics of Patients Before Propensity Score Matching.

	Aidi Injection Used
	No (N = 2950)		Yes (N = 2122)
Variable	n	%	n	%	P a
Gender					<.001
Female	1168	39.6	995	46.9
Male	1782	60.4	1127	53.1
Age, years
⩽60s	1350	45.8	1090	51.4	<.001
>60	1600	54.2	1032	48.6
Mean ± SD	59.7±10.8		59.2 ± 11.6		.296
Body mass index, kg/m2
<18.5	439	14.9	346	16.3	.146
18.5-24	1962	66.5	1419	66.9
>24	549	18.6	357	16.8
Tumor type					<.001
Gastric cancer	1482	50.2	1022	48.2
Lung cancer	636	21.6	372	17.5
Breast cancer	350	11.9	326	15.4
Colorectal cancer	270	9.2	245	11.5
Cardias and esophageal cancer	119	4.0	87	4.1
Hepatobiliary cancer	34	1.2	24	1.1
Ovarian cancer	59	2.0	46	2.2
TNM stage					.163
I-II	444	15.1	350	16.5
III-IV	2506	84.9	1772	83.5
Node metastasis					<.001
Negative	1639	55.6	1325	62.4
Positive	1311	44.4	797	37.6
Distant metastasis					<.001
Negative	1771	60.0	1454	68.5
Positive	1179	40.0	668	31.5
Prior chemotherapy					<.001
No	1742	59.1	1041	49.1
Yes	1208	40.9	1081	50.9
Prior radiotherapy					<.001
No	2792	94.6	2096	98.8
Yes	158	5.4	26	1.2
ECOG score					.038
0-1	2822	95.7	2003	94.4
⩾2	158	5.4	119	5.6
Comorbidity
Hypertension	385	13.1	268	12.6	.659
Renal insufficiency	33	1.1	66	3.1	<.001
Hepatic insufficiency	495	16.8	375	17.7	.406
Diabetes	136	4.6	111	5.2	.311
Chemotherapy regimen					<.001
Platinum and fluorouracil based	1370	46.4	1006	47.4
Platinum and pemetrexed based	215	7.3	166	7.8
Irinotecan and fluorouracil based	266	9.0	201	9.5
Platinum and taxane based	681	23.1	463	21.8
Cyclophosphamide and adriamycin based	157	5.3	157	7.4
Targeted therapy and others regimen	261	8.8	129	6.1
Other Chinese medicine
ShenqiFuzheng injection	827	28.0	756	35.6	<.001
Glycopeptide injection	764	25.9	645	30.4	<.001
Kushen injection	457	15.5	292	13.8	.087
Shenmai Injection	271	9.2	168	7.9	.113
DiyuShengbai tablet	161	5.5	143	6.7	.058
Chemotherapy cycles					<.001
1-3	1777	60.2	1402	66.1
>3	1173	39.8	720	33.9

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

^aBoldfaced P values are statistically significant.